About Us

Trishula is a clinical stage company dedicated to the development of TTX-030, a first-in-class, anti-CD39 antibody being studied in advanced cancers in multiple indications.

Leadership

Anil Singhal photo
President and CEO
Thomas Jahn photo
Chief Medical Officer
Achim Moesta photo
Vice President and Head of Immunology and Translational Sciences
Alan Luk photo
Vice President, CMC
Anh Tran photo
Head of Clinical Operations

Board of Directors

Chair, Trishula Therapeutics
Managing Director, MPM Capital
General Partner, Canaan Partners
Managing Partner, Abingworth
Board Director
Board Director
President and CEO, Trishula Therapeutics

Investors